Skip to main content

FDA Updates

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments

FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma

Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL

Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

New Indications Approved by the FDA in 2018 for Oncology Drugs

FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation

16
17
18
19
20
21
22

Page 19 of 33
Results 181 - 190 of 330